Show simple item record

dc.contributor.authorDe la Fuente López, Miguel
dc.contributor.authorLombardero, Laura
dc.contributor.authorGómez-González, Alfonso
dc.contributor.authorSolari, Cristina
dc.contributor.authorAngulo Barturen, Iñigo
dc.contributor.authorAcera Osa, Arantxa
dc.contributor.authorVecino Cordero, Elena ORCID
dc.contributor.authorAstigarraga, Egoitz
dc.contributor.authorBarreda Gómez, Gabriel
dc.date.accessioned2021-09-16T09:36:06Z
dc.date.available2021-09-16T09:36:06Z
dc.date.issued2021-08-25
dc.identifier.citationInternational Journal of Molecular Sciences 22(17) : (2021) // Article ID 9181es_ES
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10810/53101
dc.description.abstractIn recent years, enzymes have risen as promising therapeutic tools for different pathologies, from metabolic deficiencies, such as fibrosis conditions, ocular pathologies or joint problems, to cancer or cardiovascular diseases. Treatments based on the catalytic activity of enzymes are able to convert a wide range of target molecules to restore the correct physiological metabolism. These treatments present several advantages compared to established therapeutic approaches thanks to their affinity and specificity properties. However, enzymes present some challenges, such as short in vivo half-life, lack of targeted action and, in particular, patient immune system reaction against the enzyme. For this reason, it is important to monitor serum immune response during treatment. This can be achieved by conventional techniques (ELISA) but also by new promising tools such as microarrays. These assays have gained popularity due to their high-throughput analysis capacity, their simplicity, and their potential to monitor the immune response of patients during enzyme therapies. In this growing field, research is still ongoing to solve current health problems such as COVID-19. Currently, promising therapeutic alternatives using the angiotensin-converting enzyme 2 (ACE2) are being studied to treat COVID-19.es_ES
dc.description.sponsorshipThis research was funded by the Basque Government, BIKAINTEK, grant number 48-AF-W2-2019-00006; and by University of the Basque Country, PIFIND19/02, grant number 201900016247.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectbiotechnologyes_ES
dc.subjectenzyme therapyes_ES
dc.subjectencapsulationes_ES
dc.subjectmolecular modification of enzymeses_ES
dc.subjectmonitoring of immune responsees_ES
dc.subjectmicroarrayes_ES
dc.subjectCOVID-19es_ES
dc.titleEnzyme Therapy: Current Challenges and Future Perspectiveses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2021-09-09T13:47:08Z
dc.rights.holder2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/22/17/9181/htmes_ES
dc.identifier.doi10.3390/ijms22179181
dc.departamentoesBiología celular e histología
dc.departamentoeuZelulen biologia eta histologia


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).